Building on its own world-class capabilities in medical imaging and software as well as its proprietary protein quantification technology, High Sensitivity Tissue Testing (HSTT), Konica Minolta announced its intentions to revolutionise personalised patient care in 2017 with the acquisitions of Ambry Genetics, Corporation (Ambry), a top American genetic testing and analysis firm, and Invicro, LLC (Invicro), a leading provider of drug discovery support services using AI technology. The launch of KMPMJ is the latest development in Konica Minolta’s ambitious goal of transforming personalised medicine. It will also offer diagnostic and prognostic testing services using genes, proteins, and other molecules that increase physicians’ ability to assess and treat their patients’ disease. KMPMJ will provide tools to identify and track disease-linked biomarkers and related services to accelerate the development of targeted therapies. KMPMJ will be led by President Ken Masuo, a seasoned marketing executive with over 30 years of experience in the pharmaceutical industry, and will be based in Tokyo with 23 employees. The tools needed to diagnose, treat and develop new therapies Intelligent Process Monitoring for the Industry and Critical Infrastructure Rethink your work and make your business future-proof - Other Countries (MiddleEast) / English. - Other Countries (AsiaPacific) / English.- Other Countries (Americas) / English.
0 Comments
Leave a Reply. |